about
Common variable immunodeficiency syndrome with right aortic arch: a case reportXXIV World Allergy Congress 2015Clinical course and side effects of anti-IgE monoclonal antibody in patients with severe persistent asthma.Evaluation of soluble CD200 levels in type 2 diabetic foot and nephropathic patients: association with disease activityIncreased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer.Trimetazidine effect on burn-induced intestinal mucosal injury and kidney damage in rats.IL-8, IL-10, TGF-β, and GCSF levels were increased in severe persistent allergic asthma patients with the anti-IgE treatmentSoluble trail as a marker of efficacy of allergen-specific immunotherapy in patients with allergic rhinoconjunctivitis.Serum-soluble TRAIL levels in patients with severe persistent allergic asthma: its relation to omalizumab treatmentPollen aero allergens and the climate in Mediterranean region and allergen sensitivity in allergic rhinoconjunctivitis and allergic asthma patients.CXCL8, IL-1β and sCD200 are pro-inflammatory cytokines and their levels increase in the circulation of breast carcinoma patients.Association of circulating sTRAIL and high-sensitivity CRP with type 2 diabetic nephropathy and foot ulcers.Montelukast is as effective as penicillin in treatment of acute otitis media: an experimental rat study.Level of TNF-related apoptosis-inducing-ligand and CXCL8 correlated with 2-[18F]Fluoro-2-deoxy-D-glucose uptake in anti-VEGF treated colon cancers.Levofloxacin Induced Toxic Epidermal Necrolysis: Successful Therapy with Omalizumab (Anti-IgE) and Pulse PrednisoloneAn overview of the effects of anti-IgE therapies.Omalizumab (anti-IgE) therapy in the asthma-COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels.Advances in anti-IgE therapyProteomics pattern of peritoneal sApo-2L but not CD200 (OX-2) as a possible screening biomarker for metastatic ovarian, endometrial and breast carcinoma.Soluble TRAIL levels decreased in chronic hepatitis C treatment with pegylated interferon α plus ribavirin: association with viral responses.Circulating Apo 2L levels decreased in genotype II hepatitis C with pegylated interferon-2 alpha treatment.There might be a role for CD200 in the pathogenesis of autoimmune and inflammatory skin disorders.Perioperative antibiotic prophylaxis and cost in a Turkish University Hospital.The effects of climate and aero allergens changes in allergic rhinoconjunctivitis and allergic asthma patients in Mediterranean region between 2011 and 2012.D-dimer levels decreased in severe allergic asthma and chronic urticaria patients with the omalizumab treatment.Omalizumab (anti-IgE) therapy increases blood glucose levels in severe persistent allergic asthma patients with diabetes mellitus: 18 month follow-up.Effects of omalizumab on eosinophil cationic peptide, 25-hydroxyvitamin-D, IL-1β and sCD200 in cases of Samter's syndrome: 36 months follow-up.Systemic levels of ceruloplasmin oxidase activity in allergic asthma and allergic rhinitis.Health outcomes, education, healthcare delivery and quality – 3052. IL-17, IL-18, TGF-beta and GMCSF levels in patients with allergic asthma: Its relation to omalizumab treatment.Basic and clinical immunology – 3032. 18FDG-PET/CT findings (SUV-MAX) are correlated with survival in stage-4 squamous cell carcinoma.Total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide concentrations in patients with severe persistent allergic asthma: its relation to omalizumab treatment.481 Differences in Humoral and Cellular Immunity in Young and Old Individuals.Mechanisims of asthma and allergic disease – 1066. Ceruloplasmin oxidase activity in allergic asthma and allergic rhinitis.IL8 and serum soluble TRAIL levels following anti-VEGF monoclonal antibody treatment in patients with metastatic colon cancer.Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1β levels.A case of toxic epidermal necrolysis with diverse etiologies: successful treatment with intravenous immunoglobulin and pulse prednisolone and effects on sTRAIL and sCD200 levels.The relation of sTRAIL levels and quality of life in severe persistent allergic asthma patients using omalizumab.Omalizumab in symptomatic therapy of laryngeal oedema and urticaria attacts in a patient with post operative pulmonary carsinoid tumor.278 Total Antioxidant Capacity, Hydrogen Peroxide, Malondialdehyde and Total Nitric Oxide Concentrations in Patients With Severe Persistent Allergic Asthma: Its Relation to Omalizumab Treatment.Increased serum S-TRAIL level in newly diagnosed stage-IV lung adenocarcinoma but not squamous cell carcinoma is correlated with age and smoking.
P50
Q24797156-379F9C4B-F62C-48AF-8A53-939B5B61744AQ28550026-D89D2A90-DE5D-4E3B-ABBE-71290CE45D96Q33406517-0A47F403-AE37-4148-9836-B39A69A35F0DQ33856901-728F9292-FB17-4BDD-99A1-242B6A0BA12BQ34153021-6DAC99BF-D458-453C-A82B-6F98A0FB60DDQ36292376-0591D5D1-22AA-4A9A-8019-1ED690C47F90Q36506971-33E1EA95-DB6D-4C48-BB26-24B0096D9635Q36576759-7C21B145-8A1D-47F0-BBCA-CFB387486E4CQ36577451-6A54F700-2E76-4AA3-8719-18334057699EQ36774185-EE75063C-488B-43B4-AE01-196CC8621DC9Q37108096-7726091B-A4B7-4862-ADAF-9652D6ABB52DQ37145768-7B4FA4E7-DFFE-4899-AA90-089425196F15Q37255142-CB29263F-F6C7-42E7-AFED-F8419AFE993BQ37255453-A74071D6-77E5-4492-AAFF-1C737634B702Q37265230-96612B52-71E5-4C86-BEBB-7240B382D854Q38252958-472F067C-6B4E-4124-BCE3-9F38859B4C08Q40696358-12109E66-8878-4ABC-8ED5-B1670EBD434EQ40812061-32B2DE96-9A46-43EB-A42A-E188580E127BQ41207630-6989C49D-CE14-486D-9908-523D695E0FA8Q41494794-39186CB3-07AD-4B2E-B2E4-2C2831A60D94Q41569456-0EAE0714-0C27-4337-802C-E6F1C5B5DDEAQ41822047-9A37450A-68BD-4D48-8A1B-0AF40B8D3468Q42009277-19A850B0-3B1E-44F4-AFC6-68D5A346F22AQ42582842-0F48502C-6FB5-4831-B539-ECB3D1F45AF6Q44182147-61DFD055-3984-4D65-92FA-FFD49C45EAF7Q44248050-FC564373-0177-4AF4-A05B-7A5CD2F760ADQ44528029-3EE9C1CB-48C2-48F9-AED4-31E7FCE3ABF0Q45208841-E3B5DFC1-CDE7-48F9-B260-2A1E39A314DEQ45787100-CCA88EC6-3A6F-4BD7-A088-575B02E944C4Q46068656-64EA13DF-F264-4135-B03E-294FD37B723DQ46171780-73306C78-7469-4C7D-86AB-8F640A5D0046Q46599904-1DC63DCA-F071-44CA-B533-B9AA4C6988C9Q46764716-C425542F-7F8B-4B41-82DE-55930A8FFD6EQ47397422-117E2D78-B38F-44B8-8C96-AF8868D0264BQ47943679-DF9C3D00-C928-400B-96D9-C8EA51BC6E6EQ47986434-59D2C4DB-6023-49B1-AFC4-C0E239C44BFCQ48409269-562FE1C0-6A4A-4B4C-9E24-34D217574756Q49739183-FB3507EA-ABF4-4F03-B1E9-FA918664EC1AQ50348692-EFBC0B1F-7369-420D-82A8-8D50EBB256A2Q50767967-E390E241-8E5A-4B98-AF02-6A991B9ABB40
P50
name
Arzu Didem Yalcin
@en
Arzu Didem Yalcin
@nl
type
label
Arzu Didem Yalcin
@en
Arzu Didem Yalcin
@nl
prefLabel
Arzu Didem Yalcin
@en
Arzu Didem Yalcin
@nl